阿法替尼在EGFR突变的晚期非小细胞肺癌患者治疗中的预算影响分析

Budget Impact Analysis of Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation

关键词:  肺癌  EGFR突变  预算影响  阿法替尼  中国

Key words:  lung cancer  EGFR-mutation  budget impact  afatinib  China

摘要:

目的 在EGFR突变的晚期非小细胞肺癌患者的治疗中，通过评估阿法替尼（Giotrif^®）纳入中国医保报销系统将对社会总治疗费用产生的影响，为医疗保险部门提供决策依据。方法 构建预算影响分析模型，评估将阿法替尼纳入中国医保报销系统后3年（2018-2020年）对医保预算的影响。结果 阿法替尼纳入医保之前与纳入之后相比，3年内医保支付将分别减少3 644，6 632，9 620万元，3年总治疗费用支出将减少19 896万元。结论 该分析预计，将阿法替尼纳入中国医疗报销系统用于EGFR突变的晚期非小细胞肺癌患者的治疗，将降低医保总支出。

Abstract:

OBJECTIVE To evaluate the impact on total social costs for non-small cell lung cancer(NSCLC) patients with EGFR-mutation through a budget impact analysis, comparing the treatment strategy with and without afatinib(Giotrif^®) in the Chinese national reimbursement system, which would provide evidence for medical insurance decision makers. METHODS The budget impact model was constructed to assess the health care budgets changes in the 3 years (2018-2020) after afatinib was listed in Chinese national reimbursement system. RESULTS Compared with afatinib wasn't listed in health care system, total health care budgets in 3 years after afatinib was listed in would decrease by 36.44, 66.32, 96.20 million RMB, respectively. It would save 198.96 million RMB among 3 years. CONCLUSION The analysis suggests that the adoption of afatinib in the Chinese health care reimbursement list for the treatment of advanced NSCLC patients with EGFR-mutation will reduce the health care expenditure.